Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PURPOSE: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non–small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Gettinger, Scott, Rizvi, Naiyer A., Chow, Laura Q., Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E., Shepherd, Frances A., Antonia, Scott, Goldman, Jonathan W., Juergens, Rosalyn A., Laurie, Scott A., Nathan, Faith E., Shen, Yun, Harbison, Christopher T., Hellmann, Matthew D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569692/
https://ncbi.nlm.nih.gov/pubmed/27354485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.9929
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados